456 related articles for article (PubMed ID: 25141979)
21. Glycation, Glycolysis, and Neurodegenerative Diseases: Is There Any Connection?
Muronetz VI; Melnikova AK; Seferbekova ZN; Barinova KV; Schmalhausen EV
Biochemistry (Mosc); 2017 Aug; 82(8):874-886. PubMed ID: 28941455
[TBL] [Abstract][Full Text] [Related]
22. New therapeutic strategy for Parkinson's and Alzheimer's disease.
Esposito E; Cuzzocrea S
Curr Med Chem; 2010; 17(25):2764-74. PubMed ID: 20586718
[TBL] [Abstract][Full Text] [Related]
23. Role and Therapeutic Potential of RAGE Signaling in Neurodegeneration.
Kinscherf NA; Pehar M
Curr Drug Targets; 2022; 23(12):1191-1209. PubMed ID: 35702767
[TBL] [Abstract][Full Text] [Related]
24. Glycation of Wild-Type Apomyoglobin Induces Formation of Highly Cytotoxic Oligomeric Species.
Iannuzzi C; Carafa V; Altucci L; Irace G; Borriello M; Vinciguerra R; Sirangelo I
J Cell Physiol; 2015 Nov; 230(11):2807-20. PubMed ID: 25846844
[TBL] [Abstract][Full Text] [Related]
25. The Development of Maillard Reaction, and Advanced Glycation End Product (AGE)-Receptor for AGE (RAGE) Signaling Inhibitors as Novel Therapeutic Strategies for Patients with AGE-Related Diseases.
Shen CY; Lu CH; Wu CH; Li KJ; Kuo YM; Hsieh SC; Yu CL
Molecules; 2020 Nov; 25(23):. PubMed ID: 33261212
[TBL] [Abstract][Full Text] [Related]
26. Effect of glycation inhibitors on aging and age-related diseases.
Sadowska-Bartosz I; Bartosz G
Mech Ageing Dev; 2016 Dec; 160():1-18. PubMed ID: 27671971
[TBL] [Abstract][Full Text] [Related]
27. Glycation--a sweet tempter for neuronal death.
Kikuchi S; Shinpo K; Takeuchi M; Yamagishi S; Makita Z; Sasaki N; Tashiro K
Brain Res Brain Res Rev; 2003 Mar; 41(2-3):306-23. PubMed ID: 12663085
[TBL] [Abstract][Full Text] [Related]
28. Inhibitory effect of metformin and pyridoxamine in the formation of early, intermediate and advanced glycation end-products.
Ahmad S; Shahab U; Baig MH; Khan MS; Khan MS; Srivastava AK; Saeed M; Moinuddin
PLoS One; 2013; 8(9):e72128. PubMed ID: 24023728
[TBL] [Abstract][Full Text] [Related]
29. Advanced Glycation End Products: A Molecular Target for Vascular Complications in Diabetes.
Yamagishi S; Nakamura N; Suematsu M; Kaseda K; Matsui T
Mol Med; 2015 Oct; 21 Suppl 1(Suppl 1):S32-40. PubMed ID: 26605646
[TBL] [Abstract][Full Text] [Related]
30. Dietary polyphenols: regulate the advanced glycation end products-RAGE axis and the microbiota-gut-brain axis to prevent neurodegenerative diseases.
Li Y; Peng Y; Shen Y; Zhang Y; Liu L; Yang X
Crit Rev Food Sci Nutr; 2023; 63(29):9816-9842. PubMed ID: 35587161
[TBL] [Abstract][Full Text] [Related]
31. Advanced glycation end-products produced systemically and by macrophages: A common contributor to inflammation and degenerative diseases.
Byun K; Yoo Y; Son M; Lee J; Jeong GB; Park YM; Salekdeh GH; Lee B
Pharmacol Ther; 2017 Sep; 177():44-55. PubMed ID: 28223234
[TBL] [Abstract][Full Text] [Related]
32. The crucial role of metal ions in neurodegeneration: the basis for a promising therapeutic strategy.
Gaeta A; Hider RC
Br J Pharmacol; 2005 Dec; 146(8):1041-59. PubMed ID: 16205720
[TBL] [Abstract][Full Text] [Related]
33. Glycation of α-synuclein amplifies the binding with glyceraldehyde-3-phosphate dehydrogenase.
Semenyuk P; Barinova K; Muronetz V
Int J Biol Macromol; 2019 Apr; 127():278-285. PubMed ID: 30658140
[TBL] [Abstract][Full Text] [Related]
34. Glycoxidative stress creates a vicious cycle of neurodegeneration in Alzheimer's disease--a target for neuroprotective treatment strategies?
Münch G; Deuther-Conrad W; Gasic-Milenkovic J
J Neural Transm Suppl; 2002; (62):303-7. PubMed ID: 12456073
[TBL] [Abstract][Full Text] [Related]
35. Natural Products as the Potential to Improve Alzheimer's and Parkinson's Disease.
Kim SW; Lee JH; Kim B; Yang G; Kim JU
Int J Mol Sci; 2023 May; 24(10):. PubMed ID: 37240173
[TBL] [Abstract][Full Text] [Related]
36. Natural Products for the Treatment of Neurodegenerative Diseases.
Wang Z; He C; Shi JS
Curr Med Chem; 2020; 27(34):5790-5828. PubMed ID: 31131744
[TBL] [Abstract][Full Text] [Related]
37. The role of natural products in the discovery of new drug candidates for the treatment of neurodegenerative disorders I: Parkinson's disease.
Campos HC; da Rocha MD; Viegas FP; Nicastro PC; Fossaluzza PC; Fraga CA; Barreiro EJ; Viegas C
CNS Neurol Disord Drug Targets; 2011 Mar; 10(2):239-50. PubMed ID: 20874702
[TBL] [Abstract][Full Text] [Related]
38. Advanced Glycation End Products Modulate Amyloidogenic APP Processing and Tau Phosphorylation: A Mechanistic Link between Glycation and the Development of Alzheimer's Disease.
Batkulwar K; Godbole R; Banarjee R; Kassaar O; Williams RJ; Kulkarni MJ
ACS Chem Neurosci; 2018 May; 9(5):988-1000. PubMed ID: 29384651
[TBL] [Abstract][Full Text] [Related]
39. Food-derived advanced glycation end products (AGEs): a novel therapeutic target for various disorders.
Yamagishi S; Ueda S; Okuda S
Curr Pharm Des; 2007; 13(27):2832-6. PubMed ID: 17897026
[TBL] [Abstract][Full Text] [Related]
40. Advanced glycation end products and protein carbonyl levels in plasma reveal sex-specific differences in Parkinson's and Alzheimer's disease.
Sharma A; Weber D; Raupbach J; Dakal TC; Fließbach K; Ramirez A; Grune T; Wüllner U
Redox Biol; 2020 Jul; 34():101546. PubMed ID: 32460130
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
